Ketoconazole revisited: A preoperative or postoperative treatment in Cushing's disease

European Journal of Endocrinology

Volumn 158, Issue 1, 2008, Pages 91-99

  Castinetti, F ^a   Morange, I ^a   Jaquet, P ^a   Conte Devolx, B ^a   Brue, Thierry ^a  

^a TIMONE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; DEXAMETHASONE; HYDROCORTISONE; INSULIN; KETOCONAZOLE; METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA;

ADJUVANT THERAPY; ADRENALECTOMY; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; COMORBIDITY; CONTROLLED STUDY; CUSHING DISEASE; DEXAMETHASONE SUPPRESSION TEST; DIABETES MELLITUS; DIARRHEA; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERANCE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; FRANCE; GAMMA KNIFE RADIOSURGERY; HORMONAL REGULATION; HUMAN; HYDROCORTISONE URINE LEVEL; HYPERTENSION; HYPOPHYSIS ADENOMA; LONG TERM CARE; LOW DRUG DOSE; MALE; MONOTHERAPY; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; POSTOPERATIVE CARE; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; REMISSION; RETROSPECTIVE STUDY; SIDE EFFECT; SURGICAL APPROACH; SURGICAL TECHNIQUE; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; FRANCE; HUMANS; HYDROCORTISONE; KETOCONAZOLE; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PITUITARY ACTH HYPERSECRETION; POSTOPERATIVE CARE; PREOPERATIVE CARE; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 38949201006     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/EJE-07-0514     Document Type: Article

References (46)

1. Arnaldi G, Angeli A, Atkinson AB, Bertagna X, Cavagnini F, Chrousos GP, Fava GA, Findling JW, Gaillard RC, Grossman AB, Kola B, Lacroix A, Mancini T, Mantero F, Newell-Price J, Nieman LK, Sonino N, Vance ML, Giustina A & Boscaro M. Diagnosis and complications of Cushing's syndrome: a consensus statement. Journal of Clinical Endocrinology and Metabolism 2003 88 5593-5602.
2. Laws ER, Reitmeyer M, Thapar K & Vance MI. Cushing's disease resulting from pituitary corticotrophic microadenoma. Treatment results from transsphenoidal microsurgery and gamma knife radiosurgery. Neuro-Chirurgie 2002 48 294-299.
3. Bochicchio D, Losa M & Buchfelder M. Factors influencing the immediate and late outcome of Cushing's disease treated by transsphenoidal surgery: a retrospective study by the European Cushing's Disease Survey Group. Journal of Clinical Endocrinology and Metabolism 1995 80 3114-3120.
4. Burke CW Adams CB, Esiri MM, Morris C & Bevan JS. Transsphenoidal surgery for Cushing's disease: does what is removed determine the endocrine outcome? Clinical Endocrinology 1990 33 525-537.
5. Assie G, Bahurel H, Coste J, Silvera S, Kujas M, Dugue MA, Karray F, Dousset B, Bertherat J, Legmann P & Bertagna X. Corticotroph tumor progression after adrenalectomy in Cushing's disease: a reappraisal of Nelson's syndrome. Journal of Clinical Endocrinology and Metabolism 2007 92 172-179.
6. Estrada J, Boronat M, Mielgo M, Magallon R, Millan I, Diez S, Lucas T & Barcelo B. The long-term outcome of pituitary irradiation after unsuccessful transsphenoidal surgery in Cushing's disease. New England Journal of Medicine 1997 336 172-177.
7. Sonino N, Zielezny M, Fava GA, Fallo F & Boscaro M. Risk factors and long-term outcome in pituitary-dependent Cushing's disease. Journal of Clinical Endocrinology and Metabolism 1996 81 2647-2652.
8. Castinetti F, Nagai M, Dufour H, Kuhn JM, Morange I, Jaquet P, Conte-Devolx B, Regis J & Brue T. Gamma knife radiosurgery is a successful adjunctive treatment in Cushing's disease. European Journal of Endocrinology 2007 156 91-98.
9. Laws ER, Sheehan JP, Sheehan JM, Jagnathan J, Jane JA, Jr & Oskouian R. Stereotactic radiosurgery for pituitary adenomas: a review of the literature. Journal of Neuro-Oncology 2004 69 257-272.
10. Brada M, Ajithkumar TV & Minniti G. Radiosurgery for pituitary adenomas. Clinical Endocrinology 2004 61 531-543.
11. Luton JP, Mahoudeau JA, Bouchard P, Thieblot P, Hautecouverture M, Simon D, Laudat MH, Touitou Y & Bricaire H. Treatment of Cushing's disease by O,p'DDD. Survey of 62 cases. New England Journal of Medicine 1979 300 459-464.
12. Robinson BG, Hales IB, Henniker AJ, Ho K, Luttrell BM, Smee IR & Stiel JN. The effect of o,p'-DDD on adrenal steroid replacement therapy requirements. Clinical Endocrinology 1987 27 437-444.
13. Cooper PR & Shucart WA. Treatment of Cushing's disease with o,p'-DDD. New England Journal of Medicine 1979 301 48-49.
14. Verhelst JA, Trainer PJ, Howlett TA, Perry L, Rees LH, Grossman AB, Wass JA & Besser GM. Short and long-term responses to metyrapone in the medical management of 91 patients with Cushing's syndrome. Clinical Endocrinology 1991 35 169-178.
15. Miller JW & Crapo L. The medical treatment of Cushing's syndrome. Endocrine Reviews 1993 14 443-458.
16. Ambrosi B, Dall'Asta C, Cannavo, S, Libe R, Vigo T, Epaminonda P, Chiodini I, Ferrero S, Trimarchi F, Arosio M & Beck-Peccoz P. Effects of chronic administration of PPAR-gamma ligand rosiglitazone in Cushing's disease. European Journal of Endocrinology 2004 151 173-178.
17. Cannavo S, Arosio M, Almoto B, Dall'Asta C & Ambrosi B. Effectiveness of long-term rosiglitazone administration in patients with Cushing's disease. Clinical Endocrinology 2005 63 118-119.
18. Barbaro D, Lapi P, Orsini P, Pasquini C & Ciaccio S. Pioglitazone treatment in Cushing's disease. Journal of Endocrinological Investigation 2005 28 388-389.
19. Sonino N. The use of ketoconazole as an inhibitor of steroid production. New England Journal of Medicine 1987 317 812-818.
20. Feldman D. Ketoconazole and other imidazole derivatives as inhibitors of steroidogenesis. Endocrine Reviews 1986 7 409-420.
21. Loose DS, Stover EP & Feldman D. Ketoconazole binds to glucocorticoid receptors and exhibits glucocorticoid antagonist activity in cultured cells. Journal of Clinical Investigation 1983 72 404-408.
22. Pardes E, De Yampey JE, Moses DF & De Nicola AF. Regulation of glucocorticoid receptors in human mononuclear cells: effects of glucocorticoid treatment, Cushing's disease and ketoconazole Journal of Steroid Biochemistry and Molecular Biology 1991 39 233-238.
23. Loli P, Berselli ME & Tagliaferri M. Use of ketoconazole in the treatment of Cushing's syndrome. Journal of Clinical Endocrinology and Metabolism 1986 63 1365-1371.
24. Tabarin A, Navarranne A, Guerin J, Corcuff JB, Parneix M & Roger P. Use of ketoconazole in the treatment of Cushing's disease and ectopic ACTH syndrome. Clinical Endocrinology 1991 34 63-69.
25. Angeli A & Frairia R. Ketoconazole therapy in Cushing's disease. Lancet 1985 1 821.
26. Terzolo M, Panarelli M, Piovesan A, Torta M, Paccotti P & Angeli A. Ketoconazole treatment in Cushing's disease. Effect on the circadian profile of plasma ACTH and cortisol. Journal of Endocrinological Investigation 1988 11 717-721.
27. Sonino N, Boscaro M, Merola G & Mantero F. Prolonged treatment of Cushing's disease by ketoconazole. Journal of Clinical Endocrinology and Metabolism 1985 61 718-722.
28. Mortimer RH, Cannell GR, Thew CM & Galligan JP. Ketoconazole and plasma and urine steroid levels in Cushing's disease. Clinical and Experimental Pharmacology and Physiology 1991 18 563-569.
29. Farwell AP, Devlin JT & Stewart JA. Total suppression of cortisol excretion by ketoconazole in the therapy of the ectopic adrenocorticotropic hormone syndrome. American Journal of Medicine 1988 84 1063-1066.
30. Sonino N, Boscaro M, Paoletta. A, Mantero F & Ziliotto D. Ketoconazole treatment in Cushing's syndrome: experience in 34 patients. Clinical Endocrinology 1991 35 347-352.
31. Chou SC & Lin JD. Long-term effects of ketoconazole in the treatment of residual or recurrent Cushing's disease. Endocrine Journal 2000 47 401-406.
32. Arnott RD, Pestell RG, McKelvie PA, Henderson JK, McNeill PM & Alford FP. A critical evaluation of transsphenoidal pituitary surgery in the treatment of Cushing's disease: prediction of outcome. Acta Endocrinologica 1990 123 423-430.
33. Bakiri F, Tatai S, Aouali R, Semrouni M, Derome P, Chitour F & Benmiloud M. Treatment of Cushing's disease by transsphenoidal, pituitary microsurgery: prognosis factors and long-term follow-up. Journal of Endocrinological Investigation 1996 19 572-580.
34. Vallette-Kasic S, Dufour H, Mugnier M, Trouillas J, Valdes-Socin H, Caron P, Morange S, Girard N, Grisoli F, Jaquet P & Brue T. Markers of tumor invasion are major predictive factors for the long-term outcome of corticotroph microadenomas treated by transsphenoidal adenomectomy. European Journal of Endocrinology 2000 143 761-768.
35. Cerdas S, Billaud L, Guilhaume B, Laudat MH, Bertagna X & Luton JP, Short term effects of ketoconazole in Cushing's syndrome. Annales d'Endocrinologie 1989 50 489-496.
36. McCance DR, Hadden DR, Kennedy L, Sheridan B & Atkinson AB. Clinical experience with ketoconazole as a therapy for patients with Cushing's syndrome. Clinical Endocrinology 1987 27 593-599.
37. Engelhardt D & Weber MM. Therapy of Cushing's syndrome with steroid biosynthesis inhibitors. Journal of Steroid Biochemistry and Molecular Biology 1994 49 261-267.
38. Totani Y, Niinomi M, Takatsuki K, Oiso Y & Tomita A. Effect of metyrapone pretreatment on adrenocorticotropin secretion induced by corticotropin-releasing hormone in normal subjects and patients with Cushing's disease. Journal of Clinical Endocrinology and Metabolism 1990 70 798-803.
39. Dickstein G, Lahav M, Shen-Orr Z, Edoute Y & Barzilai D. Primary therapy for Cushing's disease with metyrapone. Journal of the American Medical Association 1986 255 1167-1169.
40. Chu JW, Matthias DF, Belanoff J, Schatzberg A, Hoffman AR & Feldman D. Successful long-term treatment of refractory Cushing's disease with high-dose mifepristone (RU 486). Journal of Clinical Endocrinology and Metabolism 2001 86 3568-3573.
41. Croughs RJ, Koppeschaar HP, van't Verlaat JW & McNicol AM. Bromocriptine-responsive Cushing's disease associated with anterior pituitary corticotroph hyperplasia or normal pituitary gland. Journal of Clinical Endocrinology and Metabolism 1989 68 495-498.
42. Schulte HM, Benker G, Reinwein D, Sippell WG & Allolio B. Infusion of low dose etomidate: correction of hypercortisolemia in patients with Cushing's syndrome and dose-response relationship in normal subjects. Journal of Clinical Endocrinology and Metabolism 1990 70 1426-1430.
43. Greening JE, Brain CE, Perry LA, Mushtaq I, Sales Marques J, Grossman AB & Savage MO. Efficient short-term control of hypercortisolaemia by low-dose etomidate in severe paediatric Cushing's disease. Hormone Research 2005 64 140-143.
44. Klausner MA. Ketoconazole and hepatitis. Journal of the American Academy of Dermatology 1992 26 1028-1030.
45. Knight TE, Shikuma CY & Knight J. Ketoconazole-induced fulminant hepatitis necessitating liver transplantation. Journal of the American Academy of Dermatology 1991 25 398-400.
46. Duarte PA, Chow CC, Simmons F & Ruskin J. Fatal hepatitis associated with ketoconazole therapy. Archives of Internal Medicine 1984 144 1069-1070.